Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04043195 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
A Phase 1 study of Advanced NSCLC, sponsored by Hatim Husain.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04043195 is a Phase 1 study of Advanced NSCLC that is active but no longer recruiting, run by Hatim Husain. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04043195, a Phase 1 study of Advanced NSCLC, is active but no longer recruiting, sponsored by Hatim Husain.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (1)
California
- UC San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04043195
The ClinicalTrials.gov registry entry for NCT04043195 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hatim Husain, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced NSCLC appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT04043195 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04043195 about?
NCT04043195 is a clinical study titled "Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC". The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).
What is the current status of trial NCT04043195?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-08-14. Estimated completion is 2026-12.
What conditions does trial NCT04043195 study?
This clinical trial studies the following conditions: Advanced NSCLC.
What interventions are being tested in trial NCT04043195?
The interventions under investigation include: Oxaliplatin (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04043195?
This trial is sponsored by Hatim Husain, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04043195 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.